Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers

v3.21.2
Revenues from Contracts and Significant Customers
 9 Months Ended
Sep. 30, 2021
Revenues from Contracts and Significant Customers  
Revenues from Contracts and Significant Customers

19. Revenues from Contracts and Significant Customers

Disaggregation of Total Revenue

Product revenue comprises Journey’s seven marketed products: Targadox®, Luxamend®, Ceracade®, Exelderm®, Ximino®, Accutane® and Qbrexza®. Substantially all of the product revenue is recorded in the U.S. The Company’s collaboration revenue is from Cyprium’s agreement with Sentynl (see Note 3). The Company’s related party revenue is from Checkpoint’s collaborations with TGTX. The table below summarizes the Company’s revenue for the three and nine months ending September 30, 2021 and 2020:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended September 30, 

​

Nine Months Ended September 30, 

​

    

2021

    

2020

    

2021

    

2020

Revenue

​

​

​

​

​

​

​

​

​

​

​

​

Product revenue, net

​

$

19,610

​

$

9,447

​

$

45,617

​

$

30,808

Collaboration revenue

​

​

1,446

​

​

—

​

​

4,646

​

​

—

Revenue – related party

​

 

29

​

 

28

​

 

252

​

 

1,042

Net revenue

​

$

21,085

​

$

9,475

​

$

50,515

​

$

31,850

​

Significant Customers

For the three months ended September 30, 2021, one of the Company’s dermatology products customers accounted for more than 10% of its total gross product revenue at 10.1%.  For the nine months ended September 30, 2021, none of the Company’s dermatology products customers accounted for more than 10% of its total gross product revenue.

For the three months ended September 30, 2020, none of the Company’s dermatology products customers accounted for more than 10% of its total gross product revenue. For the nine months ended September 30, 2020, one of the Company’s dermatology products customers accounted for more than 10% of its total gross product revenue.  

At September 30, 2021, two of the Company’s dermatology products customers accounted for more than 10% of its total accounts receivable balance at 20.7% and 14.9%. At December 31, 2020, one of the Company’s dermatology products customers accounted for more than 10% of its total accounts balance at 14.5%.